

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)**

Interim Condensed Consolidated Financial Statements
For the three months period ended 31 March 2020

INDEX	PAGE
Independent auditor's review report	1
Interim condensed consolidated statement of financial position	2
Interim condensed consolidated statement of income	3
Interim condensed consolidated statement of comprehensive income	4
Interim condensed consolidated statement of changes in equity	5
Interim condensed consolidated statement of cash flows	6
Notes to the interim condensed consolidated financial statements	7 – 13



Ernst & Young & Co. (Certified Public Accountants) Registration No. 45/11/323
General Partnership C.R. No. 1010383821
Head Office
Al Faisaliah Office Tower, 14th Floor
King Fahad Road
P.O. Box 2732
Riyadh 11461
Kingdom of Saudi Arabia

Tel: +966 11 215 9898
+966 11 273 4740
Fax: +966 11 273 4730
ey.ksa@sa.ey.com
ey.com/mena

**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS TO THE SHAREHOLDERS OF
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY
(SAUDI JOINT STOCK COMPANY)**

Introduction:

We have reviewed the accompanying interim condensed consolidated statement of financial position of Dr. Sulaiman Al Habib Medical Services Company ("the Company") and its subsidiaries (collectively referred to as "the Group") as at 31 March 2020, and the related interim condensed consolidated statements of income, comprehensive income, changes in equity and cash flows for the three months period then ended, and a summary of significant accounting policies and other explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of Review:

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" endorsed in the Kingdom of Saudi Arabia. A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion:

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 that is endorsed in the Kingdom of Saudi Arabia.

for Ernst & Young

Fahad M. Al-Toaimi
Certified Public Accountant
License No. (354)



Riyadh: 6 Ramadan 1441H
(29 April 2020)

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of financial position
As at 31 March 2020


	Notes	31 March 2020 SR (Unaudited)	31 December 2019 SR (Audited)
Assets			
Current assets			
Cash and cash equivalents		1,532,828,950	1,196,660,642
Accounts receivable		1,247,342,735	1,507,139,583
Advances to suppliers and contractors		19,349,799	16,583,711
Prepaid expenses and other assets		253,772,354	268,741,036
Inventories		361,758,075	295,866,976
Total current assets		3,415,051,913	3,284,991,948
Non-current assets			
Investments in associates		39,240,204	40,032,012
Property and equipment	6	5,126,969,775	5,142,278,772
Total non-current assets		5,166,209,979	5,182,310,784
Total assets		8,581,261,892	8,467,302,732
Liabilities and equity			
Liabilities			
Current liabilities			
Current portion of long-term loans		244,052,086	239,884,588
Accounts payable		603,480,868	655,968,945
Advances from customers		55,830,229	43,457,118
Accrued expenses and other liabilities		425,225,504	415,455,083
Zakat payable		55,230,631	88,031,626
Current portion of government grant		3,068,006	3,068,006
Current portion of lease liabilities		51,913,891	49,413,705
Total current liabilities		1,438,801,215	1,495,279,071
Non-current liabilities			
Long-term loans		1,716,435,383	1,780,258,784
Government grant		64,105,132	64,872,136
Lease liabilities		259,352,663	268,788,177
Employees' end-of-service benefits		278,665,920	267,310,792
Total non-current liabilities		2,318,559,098	2,381,229,889
Total liabilities		3,757,360,313	3,876,508,960
Equity			
Issued and paid-up share capital		3,500,000,000	3,500,000,000
Statutory reserve		467,872,574	467,872,574
Retained earnings		668,573,095	426,004,145
Equity attributable to equity holders of the parent		4,636,445,669	4,393,876,719
Non-controlling interests		187,455,910	196,917,053
Total equity		4,823,901,579	4,590,793,772
Total liabilities and equity		8,581,261,892	8,467,302,732



APPROVED BY:
FAISSAL AL NASSAR
CFO



APPROVED BY:
NASSER AL HAQBANI
CEO



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of income
For the three months period ended 31 March 2020

	Notes	2020 SR (Unaudited)	2019 SR (Audited)
Revenue		1,343,342,866	1,227,903,147
Cost of revenue		(943,491,727)	(823,705,255)
Gross profit		399,851,139	404,197,892
Selling and marketing expenses		(35,169,545)	(39,277,235)
General and administrative expenses		(106,074,144)	(116,744,595)
Operating income		258,607,450	248,176,062
Share of income of associates		208,192	1,561,516
Finance costs		(15,549,515)	(6,369,420)
Other income, net		16,589,636	16,579,272
Income before zakat		259,855,763	259,947,430
Zakat		(22,874,075)	(26,328,177)
Income for the period		236,981,688	233,619,253
Attributable to:			
Equity holders of the Parent		246,599,318	234,080,241
Non-controlling interests		(9,617,630)	(460,988)
		236,981,688	233,619,253
Earnings per share:	8		
Basic and diluted earnings per share from operating income		0.74	0.71
Basic and diluted earnings per share from income for the period attributable to equity holders of the parent		0.70	0.67



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
NASSER AL HAQBANI
CEO




APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of comprehensive income
For the three months period ended 31 March 2020

	Notes	2020 SR (Unaudited)	2019 SR (Audited)
Income for the period		236,981,688	233,619,253
Other comprehensive income			
<i>Items that will not to be reclassified to profit or loss in subsequent periods:</i>			
Remeasurement loss on employees' end-of-service benefits		(3,873,881)	(1,496,175)
Other comprehensive loss for the period		(3,873,881)	(1,496,175)
Total comprehensive income for the period		233,107,807	232,123,078
Attributable to:			
Equity holders of the parent company		242,568,950	232,584,066
Non-controlling interests		(9,461,143)	(460,988)
		233,107,807	232,123,078



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
NASSER AL HAQBANI
CEO



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN




Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)

Interim condensed consolidated statement of changes in equity
For the three months period ended 31 March 2020


	Attributable to equity holders of the parent					Non-controlling interests	Total equity
	Issued and paid-up share capital	Statutory reserve	Retained earnings	Total			
	SR	SR	SR	SR	SR	SR	
As at 1 January 2020	3,500,000,000	467,872,574	426,004,145	4,393,876,719	196,917,053	4,590,793,772	
Income (loss) for the period	-	-	246,599,318	246,599,318	(9,617,630)	236,981,688	
Other comprehensive loss	-	-	(4,030,368)	(4,030,368)	156,487	(3,873,881)	
Total comprehensive income (loss)	-	-	242,568,950	242,568,950	(9,461,143)	233,107,807	
As at 31 March 2020 (Unaudited)	3,500,000,000	467,872,574	668,573,095	4,636,445,669	187,455,910	4,823,901,579	
As at 1 January 2019	3,500,000,000	380,849,457	447,172,841	4,328,022,298	229,236,937	4,557,259,235	
Income (loss) for the period	-	-	234,080,241	234,080,241	(460,988)	233,619,253	
Other comprehensive (loss)	-	-	(1,496,175)	(1,496,175)	-	(1,496,175)	
Total comprehensive income (loss)	-	-	232,584,066	232,584,066	(460,988)	232,123,078	
Dividends (note 8)	-	-	(210,000,000)	(210,000,000)	-	(210,000,000)	
As at 31 March 2019 (Audited)	3,500,000,000	380,849,457	469,756,907	4,350,606,364	228,775,949	4,579,382,313	



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
NASSER AL HAQBANI
CEO



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN




Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Interim condensed consolidated statement of cash flows
For the three months period ended 31 March 2020


	2020 SR (Unaudited)	2019 SR (Audited)
Operating activities		
Income before zakat	259,855,763	259,947,430
Non-cash adjustments to reconcile income before zakat to net cash flow		
Depreciation	78,068,212	56,307,241
Share of income of associates	(208,192)	(1,561,516)
Allowance for expected credit loss	15,902,364	19,579,996
Finance costs	15,549,515	6,369,420
Employees' end-of-service benefits	14,864,966	13,568,632
	384,032,628	354,211,203
Working capital adjustments:		
Accounts receivable	243,894,484	23,462,268
Advances to suppliers and contractors	(2,766,088)	(3,937,597)
Due from/to related parties, net	-	48,298,938
Inventories	(65,838,157)	(11,566,287)
Prepaid expenses and other assets	15,794,311	8,517,760
Accounts payable	(52,488,077)	(4,054,966)
Advances from customers	12,373,111	1,321,964
Accrued expenses and other liabilities	4,468,392	26,028,746
Cash generated from operations	539,470,604	442,282,029
Zakat paid	(55,675,070)	(56,753,899)
Employees' end-of-service benefits paid	(7,383,719)	(5,293,064)
Net cash from operating activities	476,411,815	380,235,066
Investing activities		
Purchase of property and equipment	(62,630,681)	(143,394,898)
Cash flows arising on transfer of a subsidiary	-	(2,772,641)
Dividends from an associate	1,000,000	-
Net cash used in investing activities	(61,630,681)	(146,167,539)
Financing activities		
(Re-payment of) proceeds from long-term loans, net	(60,422,907)	60,022,188
Lease obligation paid	(7,942,433)	(10,210,750)
Finance costs paid	(10,247,486)	(4,041,589)
Dividends paid	-	(148,345,143)
Net cash used in financing activities	(78,612,826)	(102,575,294)
Net increase in cash and cash equivalents	336,168,308	131,492,233
Cash and cash equivalents at the beginning of the period	1,196,660,642	1,369,118,427
Cash and cash equivalents at the end of the period	1,532,828,950	1,500,610,660
Non-cash transactions:		
Recognition of right-of-use assets	1,007,105	227,616,107
Recognition of lease liabilities	1,007,105	209,036,772



APPROVED BY:
FAISAL AL NASSAR
CFO



APPROVED BY:
NASSER AL HAQBANI
CEO



APPROVED BY:
DR. SULAIMAN AL HABIB
CHAIRMAN

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements
31 March 2020

1. Corporate information and activities

Dr. Sulaiman Al Habib Medical Services Group Company (the "Company") (a Saudi joint stock company) is registered in Riyadh, Kingdom of Saudi Arabia under commercial registration number 1010118330 dated 11 Jumad Thani 1414H (corresponding to 25 November 1993). The registered office is located at Olaya District, P.O. Box 91877, Riyadh 11643, KSA.

The Company operates under medical license no. 014-101-012-012-00129 dated 26 Jumad Thani 1428H (corresponding to 11 July 2007) issued by the Ministry of Health. The Company also operates its drug stores under license No. 6375/P dated 13 Rabi Awal 1432H (corresponding to 16 February 2011) issued by Food and Drugs Administration organization.

The Company objectives include establishing and managing hospitals, medical centres, laboratories and radiology, purchasing of lands for the purpose of constructing buildings and investing in these buildings by selling and leasing for the benefit of the Company and invest in other companies through holding a controlling position. In addition, the Company also does trading in wholesale and retail of medicines, cosmetics, medical equipment and beauty products.

The Company operates a branch in Riyadh, Kingdom of Saudi Arabia "Branch of Dr. Sulaiman Al Habib Medical Services Group Company" ("the Branch") under commercial registration number 1010357146 dated 24 Muharram 1434H (corresponding to 8 December 2012). The objectives of the Branch include trading in wholesale and retail of cosmetics and maintenance of medical equipment. The Branch operates its drug store under license no. 06-01-00231 dated 24 Muharram 1435H (corresponding to 27 November 2013) issued by Food and Drugs Administration organization.

The Company operates a branch in the Kingdom of Bahrain "Dr. Sulaiman Al-Habib Medical Services Group Holding Company - Foreign Branch" ("the Foreign Branch") under commercial registration number 81609-1 dated 22 Rajab 1433H (corresponding to 12 June 2012). The objectives of the Foreign Branch include management and development of medical units in addition to providing medical supplies.

The interim condensed consolidated financial statements include the financial information of the branches mentioned above and subsidiaries mentioned in note 3.

2. Basis of preparation

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements that are endorsed by Saudi Organization for Certified Public Accountants (collectively referred to as "IFRS" as endorsed in Kingdom of Saudi Arabia").

The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should therefore be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2019.

These interim condensed consolidated financial statements are prepared on a historical cost basis except for government grants and long-term loans from Ministry of Finance, which are presented on a fair value basis. The interim condensed consolidated financial statements are presented in Saudi Riyals, which is the functional, and presentation currency of the Company and all values are rounded to the nearest one Riyal, except when otherwise indicated.

**Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
31 March 2020**

3. Basis of consolidation

These interim condensed consolidated financial statements comprise the financial statements of the Company and its following subsidiaries (collectively referred to as "the Group"), domiciled in Kingdom of Saudi Arabia ("KSA") and United Arab Emirates ("UAE") as at 31 March 2020 & 31 December 2019:

	Country of incorporation and business	Activities	Ownership %	
			<u>31 March 2019</u>	<u>31 December 2018</u>
Sehat Al Olaya Medical Complex Company	KSA	Hospital	100%	100%
Asharq Alawsat Pharmacies Company ^(a)	KSA	Pharmacy	100%	100%
Dr. Sulaiman Al Habib Hospital FZ – LLC	UAE	Hospital	100%	100%
Buraidah Al Takhassusi Hospital for Healthcare Company	KSA	Hospital	100%	100%
Al Rayan Hospital for Healthcare Company	KSA	Hospital	100%	100%
Home Healthcare Company	KSA	Home Healthcare services	100%	100%
Antab Al Riyadh for Operation and Maintenance Company	KSA	Anciliary services	100%	100%
Al Gharb Al Takhassusi Hospital For Healthcare Company	KSA	Hospital	100%	100%
Al Mokhtabarat Diagnostic Medical Company	KSA	Laboratory Services	100%	100%
Sehat Al Suwaidi Medical Company	KSA	Hospital	100%	100%
Hulool Al Sahabah for IT & Communication Company	KSA	IT Support Services	100%	100%
Al Rayan for Maintenance and Operation Company	KSA	Anciliary services	100%	100%
Al Afia Pharmacies for Medicines Company ^(a)	KSA	Pharmacy	100%	100%
Intensive Care Company for Healthcare	KSA	Hospital	100%	100%
Sehat Al Sharq Medical Limited Company	KSA	Hospital	50%	50%
Al Wosta Medical Limited Company	KSA	Hospital	50%	50%
Gharb Jeddah Hospital Company	KSA	Hospital	50%	50%
Shamal Al Riyadh for Healthcare Company	KSA	Hospital	100%	100%
Al Muhammadiya Hospital for Healthcare Company	KSA	Hospital	100%	100%

a) The other partner has assigned his shares for the benefit of the Company.

3. Basis of consolidation (continued)

Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee);
- Exposure, or rights, to variable returns from its involvement with the investee;
- The ability to use its power over the investee to affect its returns.

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee;
- Rights arising from other contractual arrangements;
- The Group's voting rights and potential voting rights.

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the interim condensed consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and non-controlling interest, even if this results in the non-controlling interest having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it:

- Derecognizes the assets and liabilities of the subsidiary;
- Derecognizes the carrying amount of any non-controlling interest;
- Recognizes the fair value of the consideration received;
- Recognizes the fair value of any investment retained;
- Recognizes any surplus or deficit in profit or loss;
- Reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss or retained earnings, as appropriate, as would be required if the Group had directly disposed of the related assets or liabilities.

4. Summary of significant accounting policies

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in preparing the Group's annual consolidated financial statements for the year ended 31 December 2019.

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
31 March 2020

5. Segment Information

Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM"). The CODM has been determined to be the Chief Financial Officer as he is primarily responsible for the allocation of resources to segments and the assessment of the performance of each of the segments.

The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group.

The identified key segments are Hospitals, Pharmacies and HMG Solutions / Others.

HMG Solutions / Others include operations with respect to Laboratories, IT Solutions, Healthcare services at doorstep Project and Staff outsourcing related to Critical Care Units with respect to Ministry of Health (Saudi Arabia).

The segment results for the period ended 31 March 2020 and the reconciliation of the segment measures to the respective statutory items included in the interim condensed consolidated financial information are as follows:

For the period ended 31 March 2020 (Unaudited)	Hospitals	Pharmacies	HMG Solutions / Others	Total
	<i>SR' millions</i>			
Saudi Arabia:				
Revenue	938	233	52	1,223
Gross profit	276	78	22	376
Outside Saudi Arabia:				
Revenue	115	4	1	120
Gross profit	22	1	1	24
Total				
Revenue	1,053	237	53	1,343
Gross profit*	298	79	23	400
Unallocated income (expenses)				
Selling and marketing				(35)
General and administrative				(106)
Operating income				259
Share of income of associates				-
Finance costs				(16)
Other income				17
Income before zakat				260
Zakat				(23)
Income for the year				237
As at 31 March 2020 (Unaudited)				
Saudi Arabia:				
Total assets	6,095	266	1,553	7,914
Total liabilities	2,493	329	819	3,641
Outside Saudi Arabia				
Total assets	623	12	32	667
Total liabilities	103	13	-	116
Total				
Total assets	6,718	278	1,585	8,581
Total liabilities	2,596	342	819	3,757

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
31 March 2020

5. Segment Information (continued)

For the period ended 31 March 19 (Audited)	Hospitals	Pharmacies	HMG Solutions / Others	Total
<i>SR' millions</i>				
Saudi Arabia:				
Revenue	894	207	20	1,121
Gross profit	310	70	12	392
Outside Saudi Arabia:				
Revenue	105	1	1	107
Gross profit	11	-	1	12
Total				
Revenue	999	208	21	1,228
Gross profit*	321	70	13	404
Unallocated income (expenses)				
Selling and marketing				(39)
General and administrative				(117)
Operating income				248
Share of income of associates				2
Finance costs				(6)
Other income				16
Income before zakat				260
Zakat				(26)
Income for the period				234
As at 31 December 2019 (Audited)				
Saudi Arabia:				
Total assets	6,431	252	1,136	7,819
Total liabilities	2,542	264	955	3,761
Outside Saudi Arabia				
Total assets	604	8	36	648
Total liabilities	103	10	3	116
Total				
Total assets	7,035	260	1,172	8,467
Total liabilities	2,645	274	958	3,877

6. Property and equipment

	As at 31 March 2020 SR (Unaudited)	As at 31 December 2019 SR (Audited)
Property and equipment	4,809,307,204	4,811,870,838
Right-of-use assets	317,662,571	330,407,934
	5,126,969,775	5,142,278,772

Dr. Sulaiman Al Habib Medical Services Group Company and its Subsidiaries
(Saudi Joint Stock Company)
Notes to the interim condensed consolidated financial statements (continued)
31 March 2020

7. Dividend distribution

The Board of Directors in their meetings during 31 March 2019 resolved to distribute interim dividends of SR 0.60 per share totaling to SR 210,000,000.

The interim dividends during the period ended 31 March 2019 were approved by the general assembly on 20/04/1441H (corresponding to 17 December 2019).

8. Earnings per share

Basic and diluted earnings per share ("EPS") is calculated by dividing the income for the period attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share is the same as the regular or basic earnings per share as the Group does not have any convertible securities or diluted instruments to exercise.

The following table reflects the operating income, income for the period attributable to equity holders of the parent and share data used in the basic and diluted EPS computations:

Basic and diluted earnings per share from operating income.

	2019 SR (Unaudited)	2018 SR (Audited)
Operating income for the period	258,607,450	248,176,062
Weighted average number of ordinary shares	350,000,000	350,000,000
Basic and diluted earnings per share from operating income	0.74	0.71

Basic and diluted earnings per share from income for the period attributable to equity holders of the parent.

	2019 SR (Unaudited)	2018 SR (Audited)
Income for the period attributable to equity holders of the parent	246,599,318	234,080,241
Weighted average number of ordinary shares	350,000,000	350,000,000
Basic and diluted earnings per share from income for the period attributable to equity holders of the parent.	0.70	0.67

9. Fair values

Financial instruments comprise financial assets and financial liabilities. Financial assets consist of cash and cash equivalents and accounts receivable. Financial liabilities consist of long-term loans, accounts payable, advances from customers, amounts due to related parties, accrued expenses and other liabilities and zakat payable.

The fair value of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of financial instruments are not materially different from their carrying values at reporting date largely.

10. Impact of COVID-19 on the financial statements

The existence of novel coronavirus (COVID-19) was confirmed in early 2020 and has spread globally including the Kingdom of Saudi Arabia (KSA), causing disruptions to many businesses and economic activities.

The extent and duration of such impacts remain uncertain and dependent on future developments that cannot be accurately predicted at this time, such as the transmission rate of the coronavirus and the extent and effectiveness of containment actions taken. Given the ongoing economic uncertainty, a reliable estimate of the impact cannot be made at the date of authorization of these interim condensed consolidated financial statements. These developments could impact the Group's future financial results, cash flows and financial condition.

11. Subsequent events

In the opinion of management, no events have occurred subsequent to the reporting date and before the issuance of these interim condensed consolidated financial statements which requires adjustment to, or disclosure, in these interim condensed consolidated financial statements.

12. Approval of the interim condensed consolidated financial statements

These interim condensed consolidated financial statements were approved for issuance by the Board of Directors on 6 Ramadan 1441H (corresponding to 29 April 2020).